{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:38:18Z","timestamp":1792723098432,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019594","name":"Yanbian University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neurot.2026.e01096","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:40:53Z","timestamp":1791808853000},"page":"e01096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunosenescence as a modifiable driver of neurodegenerative diseases: Pathways and multidimensional emerging strategies for Alzheimer's and Parkinson's diseases"],"prefix":"10.1016","volume":"23","author":[{"given":"Jingyu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linzhuo","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjian","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2026.e01096_bib1","first-page":"2937","article-title":"The expanding burden of neurodegenerative diseases: an unmet medical and social need","volume":"16","author":"Wang","year":"2024","journal-title":"Aging Dis"},{"key":"10.1016\/j.neurot.2026.e01096_bib2","first-page":"1471","article-title":"Disease-modifying drugs in Alzheimer's disease","volume":"7","author":"Ghezzi","year":"2013","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.neurot.2026.e01096_bib3","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00702-025-02893-4","article-title":"Levodopa treatment: impacts and mechanisms throughout Parkinson\u2019s disease progression","volume":"132","author":"Riederer","year":"2025","journal-title":"J Neural Transm"},{"key":"10.1016\/j.neurot.2026.e01096_bib4","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alz Res Therapy"},{"key":"10.1016\/j.neurot.2026.e01096_bib5","article-title":"Immunosenescence, aging and successful aging","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2026.e01096_bib6","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1042\/BCJ20190472","article-title":"The NLRP3 inflammasome regulates adipose tissue metabolism","volume":"477","author":"Barra","year":"2020","journal-title":"Biochem J"},{"key":"10.1016\/j.neurot.2026.e01096_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cells9081808","article-title":"The NLRP3 inflammasome: metabolic regulation and contribution to inflammaging","volume":"9","author":"Meyers","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.neurot.2026.e01096_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/antiox9080743","article-title":"ROS generation in microglia: understanding oxidative stress and inflammation in neurodegenerative disease","volume":"9","author":"Simpson","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.neurot.2026.e01096_bib9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1042\/CS20080508","article-title":"Autophagy in disease: a double-edged sword with therapeutic potential","volume":"116","author":"Martinet","year":"2009","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.neurot.2026.e01096_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-031-89525-8_1","article-title":"Understanding the blood-brain barrier: from physiology to pathology","volume":"1477","author":"Garcia-Gallardo","year":"2025","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.neurot.2026.e01096_bib11","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s43587-025-00921-2","article-title":"Metabolic regulation of immunological aging","volume":"5","author":"Kim","year":"2025","journal-title":"Nat Aging"},{"key":"10.1016\/j.neurot.2026.e01096_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-01251-0","article-title":"Aging and aging-related diseases: from molecular mechanisms to interventions and treatments","volume":"7","author":"Guo","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.neurot.2026.e01096_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-0716-0795-4_1","article-title":"Vaccine delivery and immune response basics","volume":"2183","author":"Hill","year":"2021","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.neurot.2026.e01096_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-023-01451-2","article-title":"Immunosenescence: molecular mechanisms and diseases","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.neurot.2026.e01096_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-023-01502-8","article-title":"Inflammation and aging: signaling pathways and intervention therapies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.neurot.2026.e01096_bib16","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018101064","article-title":"Systemic inflammation impairs microglial A\u03b2 clearance through NLRP3 inflammasome","volume":"38","author":"Tejera","year":"2019","journal-title":"EMBO J"},{"key":"10.1016\/j.neurot.2026.e01096_bib17","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/brain\/awv395","article-title":"Immunosenescence of microglia and macrophages: impact on the ageing central nervous system","volume":"139","author":"Rawji","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2026.e01096_bib18","article-title":"Microglia-specific overexpression of \u03b1-synuclein leads to severe dopaminergic neurodegeneration by phagocytic exhaustion and oxidative toxicity","volume":"12","author":"Bido","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2026.e01096_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-024-01816-8","article-title":"Glial senescence enhances \u03b1-synuclein pathology owing to its insufficient clearance caused by autophagy dysfunction","volume":"10","author":"Hong","year":"2024","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.neurot.2026.e01096_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae204","article-title":"Chronic inflammation with microglia senescence at basal forebrain: impact on cholinergic deficit in Alzheimer's brain haemodynamics","volume":"6","author":"Liu","year":"2024","journal-title":"Brain Commun"},{"key":"10.1016\/j.neurot.2026.e01096_bib21","doi-asserted-by":"crossref","DOI":"10.1186\/s40659-022-00379-1","article-title":"A\u03b2 promotes CD38 expression in senescent microglia in Alzheimer's disease","volume":"55","author":"Hu","year":"2022","journal-title":"Biol Res"},{"key":"10.1016\/j.neurot.2026.e01096_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/antiox11122466","article-title":"Neuronal oxidative stress promotes \u03b1-Synuclein aggregation in vivo","volume":"11","author":"Won","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.neurot.2026.e01096_bib23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jnen\/nly024","article-title":"Increased oxidative stress exacerbates \u03b1-Synuclein aggregation in vivo","volume":"77","author":"Scudamore","year":"2018","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.neurot.2026.e01096_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-023-02879-7","article-title":"H3K18 lactylation of senescent microglia potentiates brain aging and Alzheimer's disease through the NF\u03baB signaling pathway","volume":"20","author":"Wei","year":"2023","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neurot.2026.e01096_bib25","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cmet.2022.02.013","article-title":"Positive feedback regulation of microglial glucose metabolism by histone H4 lysine 12 lactylation in Alzheimer's disease","volume":"34","author":"Pan","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.neurot.2026.e01096_bib30","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.cmet.2016.05.006","article-title":"CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-Dependent mechanism","volume":"23","author":"Camacho-Pereira","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.neurot.2026.e01096_bib31","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s42255-020-00298-z","article-title":"CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD and NMN levels","volume":"2","author":"Chini","year":"2020","journal-title":"Nat Metab"},{"key":"10.1016\/j.neurot.2026.e01096_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114102","article-title":"LXR\/CD38 activation drives cholesterol-induced macrophage senescence and neurodegeneration via NAD+ depletion","volume":"43","author":"Terao","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.neurot.2026.e01096_bib27","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1091\/mbc.e06-10-0975","article-title":"Activation of microglia acidifies lysosomes and leads to degradation of alzheimer amyloid fibrils","volume":"18","author":"Majumdar","year":"2007","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.neurot.2026.e01096_bib28","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41593-019-0372-9","article-title":"Senolytic therapy alleviates A\u03b2-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer's disease model","volume":"22","author":"Zhang","year":"2019","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.neurot.2026.e01096_bib29","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.18632\/aging.205581","article-title":"Exploring the effects of dasatinib, quercetin, and fisetin on DNA methylation clocks: a longitudinal study on senolytic interventions","volume":"16","author":"Lee","year":"2024","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.neurot.2026.e01096_bib32","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.1016\/j.cell.2021.09.007","article-title":"Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes","volume":"184","author":"Scheiblich","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.neurot.2026.e01096_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.115052","article-title":"Microglia degrade Alzheimer's amyloid-beta deposits extracellularly via digestive exophagy","volume":"43","author":"Jacquet","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.neurot.2026.e01096_bib34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.it.2006.11.004","article-title":"What is immune privilege (not)?","volume":"28","author":"Galea","year":"2007","journal-title":"Trends Immunol"},{"key":"10.1016\/j.neurot.2026.e01096_bib35","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nri3265","article-title":"The anatomical and cellular basis of immune surveillance in the central nervous system","volume":"12","author":"Ransohoff","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.neurot.2026.e01096_bib36","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1126\/science.7624779","article-title":"Induction of MHC class I genes in neurons","volume":"269","author":"Neumann","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.neurot.2026.e01096_bib37","article-title":"antiCD49d Ab treatment ameliorates age-associated inflammatory response and mitigates CD8+ T-cell cytotoxicity after traumatic brain injury","volume":"21","author":"Chen","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.neurot.2026.e01096_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2025.120787","article-title":"Qizhi tongluo capsule improves vascular dementia in rats via integrated metabolomics and molecular mechanism research","volume":"356","author":"Sun","year":"2026","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.neurot.2026.e01096_bib39","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/s41593-023-01415-3","article-title":"Infiltrating CD8 T cells exacerbate Alzheimer's disease pathology in a 3D human neuroimmune axis model","volume":"26","author":"Jorfi","year":"2023","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.neurot.2026.e01096_bib40","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41582-021-00549-x","article-title":"Peripheral and central immune system crosstalk in alzheimer disease - a research prospectus","volume":"17","author":"Bettcher","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurot.2026.e01096_bib41","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1007\/s12264-021-00654-3","article-title":"Activated natural killer cells hit neurogenesis in the aging brain","volume":"37","author":"Cuapio","year":"2021","journal-title":"Neurosci Bull"},{"key":"10.1016\/j.neurot.2026.e01096_bib42","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.neurot.2026.e01096_bib43","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s43587-023-00523-w","article-title":"TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease","volume":"3","author":"Shulman","year":"2023","journal-title":"Nat Aging"},{"key":"10.1016\/j.neurot.2026.e01096_bib44","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and efficacy of semorinemab in individuals with prodromal to mild alzheimer disease: a randomized clinical trial","volume":"79","author":"Teng","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2026.e01096_bib45","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00702-025-02893-4","article-title":"Levodopa treatment: impacts and mechanisms throughout Parkinson's disease progression","volume":"132","author":"Riederer","year":"2025","journal-title":"J Neural Transm"},{"key":"10.1016\/j.neurot.2026.e01096_bib46","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00702-023-02623-8","article-title":"Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations","volume":"130","author":"Regensburger","year":"2023","journal-title":"J Neural Transm"},{"key":"10.1016\/j.neurot.2026.e01096_bib47","article-title":"A phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): rationale, design, and baseline data","volume":"132","author":"Nikolcheva","year":"2025","journal-title":"Parkinsonism Relat Disorders"},{"key":"10.1016\/j.neurot.2026.e01096_bib48","article-title":"An update on immune-based alpha-synuclein trials in Parkinson's disease","volume":"272","author":"Alfaidi","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2026.e01096_bib49","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-016-0710-8","article-title":"Infliximab reduces peripheral inflammation, neuroinflammation, and extracellular GABA in the cerebellum and improves learning and motor coordination in rats with hepatic encephalopathy","volume":"13","author":"Dadsetan","year":"2016","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neurot.2026.e01096_bib50","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41586-023-06300-4","article-title":"Co-transplantation of autologous Treg cells in a cell therapy for Parkinson's disease","volume":"619","author":"Park","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2026.e01096_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.953534","article-title":"Regulation of microglia phagocytosis and potential involvement of exercise","volume":"16","author":"Li","year":"2022","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.neurot.2026.e01096_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2016.04.060","article-title":"Nicotinamide mononucleotide protects against \u03b2-amyloid oligomer-induced cognitive impairment and neuronal death","volume":"1643","author":"Wang","year":"2016","journal-title":"Brain Res"},{"key":"10.1016\/j.neurot.2026.e01096_bib53","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.tem.2025.03.013","article-title":"NAD augmentation as a disease-modifying strategy for neurodegeneration","volume":"36","author":"D\u00f6lle","year":"2025","journal-title":"Trends Endocrinol Metabol"},{"key":"10.1016\/j.neurot.2026.e01096_bib54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s42255-018-0009-4","article-title":"Slc12a8 is a nicotinamide mononucleotide transporter","volume":"1","author":"Grozio","year":"2019","journal-title":"Nat Metab"},{"key":"10.1016\/j.neurot.2026.e01096_bib55","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JPD-181503","article-title":"Semaglutide is neuroprotective and reduces \u03b1-Synuclein levels in the chronic MPTP mouse model of parkinson's disease","volume":"9","author":"Zhang","year":"2019","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.neurot.2026.e01096_bib56","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-024-01666-7","article-title":"Evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease","volume":"17","author":"Cummings","year":"2025","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurot.2026.e01096_bib57","article-title":"Dietary supplementation with N-acetylcysteine confers a protective effect on muscle and liver in lipopolysaccharide-challenged piglets","volume":"11","author":"Li","year":"2024","journal-title":"Front Nutr"},{"key":"10.1016\/j.neurot.2026.e01096_bib58","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.expneurol.2018.09.011","article-title":"Early intrathecal infusion of everolimus restores cognitive function and mood in a murine model of Alzheimer's disease","volume":"311","author":"Cassano","year":"2019","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurot.2026.e01096_bib59","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11064-012-0909-8","article-title":"Therapeutic effects of rapamycin on MPTP-induced parkinsonism in mice","volume":"38","author":"Liu","year":"2013","journal-title":"Neurochem Res"},{"key":"10.1016\/j.neurot.2026.e01096_bib60","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","article-title":"ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease","volume":"1","author":"Novak","year":"2021","journal-title":"Nat Aging"},{"key":"10.1016\/j.neurot.2026.e01096_bib61","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01096_bib62","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1523\/JNEUROSCI.2427-21.2022","article-title":"Microglial mTOR activation upregulates Trem2 and enhances \u03b2-Amyloid plaque clearance in the 5XFAD alzheimer's disease model","volume":"42","author":"Shi","year":"2022","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurot.2026.e01096_bib63","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/2211-5463.13300","article-title":"Reduced TREM2 activation in microglia of patients with Alzheimer's disease","volume":"11","author":"Okuzono","year":"2021","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.neurot.2026.e01096_bib64","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.neuroscience.2016.04.033","article-title":"Inhibition of cerebral vascular inflammation by brain endothelium-targeted oligodeoxynucleotide complex","volume":"329","author":"Hu","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/j.neurot.2026.e01096_bib65","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.toxrep.2019.04.004","article-title":"Role of nanostructures in improvising oral medicine","volume":"6","author":"Ghosh","year":"2019","journal-title":"Toxicol Rep"},{"key":"10.1016\/j.neurot.2026.e01096_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202405781","article-title":"Intranasal delivery of pure nanodrug loaded liposomes for alzheimer's disease treatment by efficiently regulating microglial polarization","volume":"20","author":"Feng","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.neurot.2026.e01096_bib67","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-022-00547-7","article-title":"Novel app knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia","volume":"17","author":"Xia","year":"2022","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.neurot.2026.e01096_bib68","article-title":"Stealth missiles with precision guidance: a novel multifunctional nano-drug delivery system based on biomimetic cell membrane coating technology","volume":"33","author":"Zhou","year":"2025","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.neurot.2026.e01096_bib69","doi-asserted-by":"crossref","first-page":"9800","DOI":"10.1021\/jacs.4c18455","article-title":"Enhancing T-Cell infiltration and immunity in solid tumors via DNA Nanolinker-Mediated monocyte hitchhiking","volume":"147","author":"Wen","year":"2025","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.neurot.2026.e01096_bib70","article-title":"Human lymph node cellular senescence atlas reveals age-dependent alteration in germinal center B cell function and niches","author":"Farzad","year":"20260402","journal-title":"bioRxiv"},{"key":"10.1016\/j.neurot.2026.e01096_bib71","article-title":"Single-microglia transcriptomic transition network-based prediction and real-world patient data validation identifies ketorolac as a repurposable drug for Alzheimer's disease","volume":"21","author":"Xu","year":"2025","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.neurot.2026.e01096_bib72","article-title":"High-resolution spatial profiling of microglia reveals proximity associated immunometabolic reprogramming in alzheimer's disease","author":"Saito","year":"20250516","journal-title":"bioRxiv"},{"key":"10.1016\/j.neurot.2026.e01096_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26157498","article-title":"The redox revolution in brain medicine: targeting oxidative stress with AI, multi-omics and mitochondrial therapies for the precision eradication of neurodegeneration","volume":"26","author":"\u015eerban","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurot.2026.e01096_bib74","first-page":"1663","article-title":"Computational drug repurposing in Parkinson's disease: omaveloxolone and cyproheptadine as promising therapeutic candidates","volume":"16","author":"Guo","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.neurot.2026.e01096_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113889","article-title":"Discovery of PT-65 as a highly potent and selective proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease","volume":"226","author":"Qu","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.neurot.2026.e01096_bib76","doi-asserted-by":"crossref","DOI":"10.1007\/s11481-025-10209-2","article-title":"HucMSCs-Derived extracellular vesicles deliver RPS27A protein to manipulate the MDM2-P53 axis and ameliorate neurological dysfunction in parkinson's disease","volume":"20","author":"Xu","year":"2025","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1016\/j.neurot.2026.e01096_bib77","doi-asserted-by":"crossref","DOI":"10.1007\/s11481-025-10245-y","article-title":"TNF-\u03b1 inhibition modulates CX3CR1, pyroptosis-related genes, and BDNF to alleviate anxiety-like behavior in type 2 diabetic rats","volume":"20","author":"Septyaningtrias","year":"2025","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1016\/j.neurot.2026.e01096_bib78","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.csbj.2025.02.014","article-title":"Protein design accelerates the development and application of optogenetic tools","volume":"27","author":"Zhu","year":"2025","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.neurot.2026.e01096_bib79","doi-asserted-by":"crossref","DOI":"10.1186\/s40168-018-0439-y","article-title":"Microbiome-host systems interactions: protective effects of propionate upon the blood-brain barrier","volume":"6","author":"Hoyles","year":"2018","journal-title":"Microbiome"},{"key":"10.1016\/j.neurot.2026.e01096_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2016.00256","article-title":"Effect of probiotic supplementation on cognitive function and metabolic status in alzheimer's disease: a randomized, double-blind and controlled trial","volume":"8","author":"Akbari","year":"2016","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.neurot.2026.e01096_bib81","doi-asserted-by":"crossref","DOI":"10.1007\/s44368-026-00029-8","article-title":"Gut microbiome immune interactions drive neuroinflammation and neurodegeneration in Parkinson's disease","volume":"3","author":"Jadhav","year":"2026","journal-title":"Discov Immun"},{"key":"10.1016\/j.neurot.2026.e01096_bib82","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/dta.3691","article-title":"Analytical and behavioral characterization of 1-dodecanoyl-LSD (1DD-LSD)","volume":"17","author":"Kavanagh","year":"2025","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.neurot.2026.e01096_bib83","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-65061-w","article-title":"A neurotherapeutic approach with Lacticaseibacillus rhamnosus E9 on gut microbiota and intestinal barrier in MPTP-induced mouse model of Parkinson's disease","volume":"14","author":"Aktas","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2026.e01096_bib84","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520925930","article-title":"Rapid improvement in Alzheimer's disease symptoms following fecal microbiota transplantation: a case report","volume":"48","author":"Hazan","year":"2020","journal-title":"J Int Med Res"},{"key":"10.1016\/j.neurot.2026.e01096_bib85","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1038\/s41591-023-02543-w","article-title":"Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial","volume":"29","author":"Gonzales","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2026.e01096_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20133161","article-title":"Recent developments in TSPO PET imaging as A biomarker of neuroinflammation in neurodegenerative disorders","volume":"20","author":"Werry","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurot.2026.e01096_bib87","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13209","article-title":"Role of estrogen in women's Alzheimer's disease risk as modified by APOE","volume":"35","author":"Valencia-Olvera","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.neurot.2026.e01096_bib88","first-page":"294","article-title":"Androgens and parkinson's disease: a review of human studies and animal models","volume":"2","author":"Bourque","year":"2021","journal-title":"Androg Clin Res Ther"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:54:14Z","timestamp":1792720454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926002667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":88,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1878747926002667"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01096","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosenescence as a modifiable driver of neurodegenerative diseases: Pathways and multidimensional emerging strategies for Alzheimer's and Parkinson's diseases","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e01096"}}